Showing results (31-40 of 227) with videos related to
Sort By:
Pageof 23
Clinical Lymphoma, Myeloma & Leukemia|December 28, 2020
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell LymphomaSolomon A Graf, Ryan D Cassaday, Karolyn Morris, et al.JCO Oncology Practice|November 18, 2024
Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World ExperienceIvan J Huang, Grace T Baek, Jonathan Cohen, et al.Case Reports in Hematology|March 22, 2017
Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature ReviewD Alan Potts, Jonathan R Fromm, Ajay K Gopal, et al.Cancer Investigation|February 8, 2025
Exclusion of People Living with HIV in Aggressive B-Cell Non-Hodgkin Lymphoma Studies: A Cross-Sectional Analysis of Clinical Trials from 2014 to 2024Daniel J Olivieri, Ajay K Gopal, Thomas S Uldrick, et al.Blood Research|May 13, 2022
Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8<sup>+</sup> T-cells despite immune checkpoint signalingAdam M Greenbaum, Jonathan R Fromm, Ajay K Gopal, et al.Practical Radiation Oncology|October 5, 2019
Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell LymphomaAileen Kim, Philip Stevenson, Ryan D Cassaday, et al.Current Treatment Options in Oncology|July 4, 2017
Clinical Impact of the 2016 Update to the WHO Lymphoma ClassificationRyan C Lynch, Dita Gratzinger, Ranjana H AdvaniClinical Lymphoma, Myeloma & Leukemia|January 12, 2021
Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing AnalysisStephen D Smith, Paolo Lopedote, Yazeed Samara, et al.Blood Advances|June 17, 2025
Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomasChristina Poh, Jenna M Voutsinas, Mazyar Shadman, et al.Leukemia & Lymphoma|May 15, 2024
Mitigating time toxicity in lymphoma and multiple myelomaMengyang Di, Christopher T Su, Andrew J Cowan, et al.Pageof 23